FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1802-1803 October 21, 2004 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Thompson, I. M. PubMed Citation

To the Editor: Thompson et al. (May 27 issue)¹ have provided a fascinating picture of the prevalence of prostate cancer in men with "normal" prostate-specific antigen (PSA) levels in the Prostate Cancer Prevention Trial. They found surprisingly high rates of prostate cancer in men with PSA values of 4.0 ng per milliliter or less. Many authors have pointed out that PSA screening is flawed because of its relatively poor sensitivity and specificity.² One potential strategy to improve the sensitivity of PSA evaluations in the context of metastatic disease includes "PSA velocity," or PSA doubling times.³ Since the Prostate Cancer Prevention . . . [Full Text of this Article]

This article has been cited by other articles:

• Sunami, E., Shinozaki, M., Higano, C. S., Wollman, R., Dorff, T. B., Tucker, S. J., Martinez, S. R., Singer, F. R., Hoon, D. S.B. (2009). Multimarker Circulating DNA Assay for Assessing Blood of Prostate Cancer Patients. Clin. Chem. 55: 559-567 [Abstract] [Full Text]